Phase II study of biweekly cetuximab therapy for unresectable colorectal cancer
Ontology highlight
ABSTRACT: Interventions: biweekly administration of cetuximab
Primary outcome(s): Response rate
Study Design: Single arm Non-randomized
DISEASE(S): Unresectable Colorectal Cancer
PROVIDER: 2626732 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA